Clinical trial register · Poland

Clinical Trials in Bialystok, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC

2705

Studies in scope

all four open statuses

1389

Recruiting now

open to new participants

512

Lead sponsors

across recruiting studies

Top sites

Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619

Trials with a site in Bialystok

Status

Study

Lead sponsor

Phase

Enrol

Sites in Poland

Start

Not yet open

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

NCT07789015Idiopathic Inflammatory Myopathies

DrugNerandomilast

Boehringer Ingelheim

Phase 3

270

Bialystok, Bydgoszcz, Katowice

2026-12-14

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Lublin, Gorzów Wielkopolski, Grodzisk Mazowiecki, Ostrów Mazowiecka, Warsaw, Bialystok, Częstochowa, Bielsko-Biala

2026-10-26

Not yet open

Health, Fitness, and Safety Knowledge as Determinants of Adverse Events in Recreational Divers in Poland

NCT07855861Decompression Sickness, Barotrauma, Recreational Diving

Medical University of Bialystok

Observational

384

Bialystok

2026-10-01

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335Type 2 Diabetes, Cardiovascular Risk

DrugZenagamtide

Novo Nordisk A/S

Phase 3

1,778

Lublin, Bialystok, Chorzów, Bolesławiec, Katowice, Libiąż, Lodz, Olsztyn

2026-08-24

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Bialystok, Częstochowa, Gdynia, Katowice, Krakow, Poznan, Przemyśl, Radzionków

2026-08-24

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Będzin, Bialystok, Czeladź, Gmina Świecie, Katowice, Kwidzyn, Lodz, Lublin

2026-08-21

Recruiting

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

NCT07686263Schizophrenia

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

472

Warsaw, Bialystok, Poznan

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan

2026-08-19

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Bialystok, Bielsko-Biala, Bydgoszcz, Gdansk, Krakow, Leszno, Lodz, Olkusz

2026-08-14

Recruiting

A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland

NCT07623174Metastatic Colorectal Cancer

Takeda

Observational

110

Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Opole, Przemyśl, Bialystok

2026-08-13

Recruiting

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841Overweight, Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

450

Bialystok, Bydgoszcz, Bygdoszcz, Lodz, Poznan, Staszów, Warsaw

2026-08-12

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07759245Pulmonary Disease, Chronic Obstructive

DrugBrenipatide

Eli Lilly and Company

Phase 2

606

Bialystok, Krakow

2026-08-07

Recruiting

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc

DrugsEtoposide·Atezolizumab·Carboplatin

SystImmune Inc.

Phase 3

550

Bialystok, Gdynia, Katowice, Lodz, Prabuty

2026-08-04

Recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

NCT05776927Asthma

Novartis Pharmaceuticals

Phase 3

188

Tarnów, Bialystok, Krakow, Lublin, Piaseczno, Torun

2026-08-04

Not yet open

Clinical, Radiographic and Volumetric Evaluation of the Entire Papilla Preservation Technique With and Without Connective Tissue Graft in the Treatment of Periodontal Intraosseous Defects.

NCT07737834Intrabony Periodontal Defect

Medical University of Warsaw

Not applicable

Warsaw, Bialystok, Szczecin

2026-08-01

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Bialystok, Bydgoszcz, Krakow, Poznan, Warsaw

2026-07-27

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553Type 2 Diabetes Mellitus

DrugElecoglipron

AstraZeneca

Phase 3

600

Bialystok, Częstochowa, Kielce, Krakow, Lodz, Poznan, Radom, Warsaw

2026-07-08

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

2,000

Bialystok, Częstochowa, Kielce, Lodz, Lublin, Poznan, Radom, Warsaw

2026-07-06

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Bialystok, Krakow, Lodz, Lublin, Poznan, Radom, Warsaw

2026-07-06

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom

2026-06-29

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388Diabetes Mellitus, Type 2

DrugsUBT251·Semaglutide

Novo Nordisk A/S

Phase 2

300

Lublin, Bialystok, Kielce, Oświęcim

2026-06-22

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Bialystok, Krakow, Lodz, Poznan, Rzeszów, Warsaw

2026-06-11

Recruiting

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549Obesity, Overweight and/or Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

954

Bialystok, Gdansk, Lublin, Poznan, Wroclaw

2026-06-10

Recruiting

Prevention With Ismigen of RTIs in Kids

NCT07578012Respiratory Tract Infections (RTI), Healthy Children

Lallemand Pharma AG

Phase 4

224

Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Poznan, Tarnów

2026-06-01

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641HR+/HER2- Breast Cancer

DrugsBGB-43395·Ribociclib·Abemaciclib·Palbociclib

BeOne Medicines

Phase 3

1,056

Bialystok, Gdynia, Kielce, Krakow, Opole, Otwock, Warsaw

2026-05-22

Recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414Obesity, Type 2 Diabetes

DrugsCagriSema·Semaglutide

Novo Nordisk A/S

Phase 3

2,500

Bialystok, Bydgoszcz, Dębica, Katowice, Krakow, Poznan, Rzeszów, Warsaw

2026-05-21

Not yet open

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2

DrugsNNC0487-0111·Semaglutide

Novo Nordisk A/S

Phase 3

1,000

Lublin, Grudziądz, Bialystok, Elblag, Gorzów Wielkopolski, Kalwaria Zebrzydowska, Krakow, Legnica

2026-05-20

Recruiting

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

NCT07318597Pulmonary Arterial Hypertension (PAH)

Regeneron Pharmaceuticals

Phase 2

Poznan, Bialystok, Katowice, Lodz

2026-05-06

Recruiting

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

NCT07606066Type 2 Diabetes

AstraZeneca

Observational

2,150

Lublin, Krakow, Radom, Bialystok, Częstochowa, Poznan, Warsaw, Lodz

2026-05-06

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

Bialystok, Bydgoszcz, Krakow, Warsaw

2026-04-20

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954Diabetes Mellitus, Type 2

DrugsNNC0662-0419·Semaglutide

Novo Nordisk A/S

Phase 2

270

Bialystok, Lublin, Oświęcim, Warsaw, Zabrze

2026-04-17

Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630Obesity, Knee Osteoarthritis (OA)

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

Bialystok, Bydgoszcz, Krakow, Warsaw

2026-04-13

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801Breast Cancer

DrugsInavolisib·Ribociclib·Fulvestrant

Hoffmann-La Roche

Phase 2

?ód?, Bialystok, Lublin, Wroc?aw

2026-04-07

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC

DrugsRina-S·Bevacizumab

Genmab

Phase 3

544

Bialystok

2026-04-03

Recruiting

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

NCT07415551Allergic Diseases, Chronic Spontaneous Urticaria (CSU)

Yuhan Corporation

Phase 2

150

Poznan, Krakow, Tarnów, Wroclaw, Lublin, Opole, Bialystok, Katowice

2026-03-26

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Bialystok, Bydgoszcz, Dębica, Lublin, Pabianice, Poznan, Ruda Śląska, Siedlce

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Bialystok, Bydgoszcz, Gdynia, Krakow, Lublin, Opole, Tarnów, Tychy

2026-03-16

Recruiting

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT07286058Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,182

Bialystok, Bytom, Krakow, Nowa Sól, Opole, Poznan, Sochaczew, Torun

2026-03-11

Recruiting

Preserflo MicroShunt Versus Trabeculectomy

NCT07496957GLAUCOMA 1, OPEN ANGLE, D (Disorder)

Medical University of Bialystok

Not applicable

100

Bialystok

2026-03-01

Recruiting

Poland-Italy Aortic Research Bridge Real World Registry

NCT07476196Abdominal Aortic Aneurysm

American Heart of Poland

Observational

200

Bialystok, Bielsko-Biala, Bytom, Chrzanów, Ełk, Gdynia, Kielce, Krakow

2026-03-01

Active, closed

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2

DrugBerobenatide

Pfizer

Phase 3

1,078

Lodz, Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice

2026-02-24

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Poznan, Siedlce, Bialystok, Szczecin

2026-02-16

Recruiting

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT07412756Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Bialystok, Bielsko-Biala, Gdansk, Krakow, Leszno, Poznan, Szczecin, Wroclaw

2026-02-09

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

1,980

Bialystok, Krakow, Lodz, Lublin, Poznan, Wroclaw, Zabrze

2026-02-06

Recruiting

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654Eosinophilic Asthma

DrugKT-621

Kymera Therapeutics, Inc.

Phase 2

264

Bialystok, Gdansk, Lodz, Poznan, Sosnowiec, Tarnów, Trzebnica, Wroclaw

2026-01-28

Recruiting

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 2/3

153

Bialystok, Lodz, Szczecin

2026-01-22

Recruiting

Comparative Study of Caries-Preventive Effects: 2% Calcium Hypophosphite Toothpaste vs. Sodium Fluoride Toothpaste (1450ppm F)

NCT07068204Caries, Dental, Calcium Hypophosphite, Fluoridation

Dr. Joachim Enax

Not applicable

164

Bialystok, Poznan

2026-01-22

Recruiting

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873Arthritis, Psoriatic

Janssen Research & Development, LLC

Phase 2

240

Bialystok, Bydgoszcz, Elblag, Krakow, Lublin, Nadarzyn, Olsztyn, Torun

2026-01-15

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901Obesity With Diabetes, Overweight With Diabetes

DrugRibupatide

Kailera

Phase 3

1,270

Bydgoszcz, Torun, Krakow, Lublin, Siedlce, Warsaw, Bialystok, Gdynia

2026-01-12

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07284459Idiopathic Pulmonary Fibrosis

Contineum Therapeutics

Phase 2

324

Bydgoszcz, Świdnik, Bialystok, Sosnowiec

2026-01-08

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Bialystok, Krakow, Lublin, Warsaw

2026-01-07

Recruiting

Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment

NCT07529145Non-Small Cell Carcinoma of Lung, Small Cell Carcinoma of Lung

Medical University of Bialystok

Observational

Bialystok

2026-01-01

Recruiting

Vivinex Impress XY1-EM vs RayOne EMV

NCT06891092Cataract

Medical University of Bialystok

Not applicable

100

Bialystok

2026-01-01

Recruiting

iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment

NCT07325552Open Angle Glaucoma (OAG)

Medical University of Bialystok

Not applicable

100

Bialystok

2026-01-01

Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

NCT07218523Bowel Cleansing Prior to Clinical Procedures

DrugsPicoprep·Plenvu

Norgine

Phase 3

212

Torun, Krakow, Warsaw, Bialystok, Gdansk, Zabrze

2025-12-29

Active, closed

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850Obesity and Overweight

DrugBerobenatide

Pfizer

Phase 3

3,578

Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice, Krakow

2025-12-19

Recruiting

Identification of Biomarkers of Obstructive Sleep Apnea.

NCT07723144Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA), Obstructive Sleep Apnea (OSAS), Obstructive Sleep Apnea (SAOS)

Medical University of Bialystok

Not applicable

120

Bialystok

2025-12-19

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

NCT07225686Obesity, Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

Bialystok, Poznan, Warsaw

2025-12-19

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

1,035

Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Ruda Śląska, Zabrze

2025-12-15

Recruiting

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis

UCB Biopharma SRL

Phase 1

392

Bialystok, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn

2025-12-10

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

DrugCYB003

Cybin IRL Limited

Phase 3

330

Bialystok, Bydgoszcz, Gdansk, Warsaw

2025-12-10

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Bialystok, Gdansk, Kielce, Siedlce, Szczecin

2025-12-09

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

366

Lublin, Warsaw, Bialystok, Gdansk, Lodz, Olsztyn

2025-12-03

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)

Ventus Therapeutics U.S., Inc.

Phase 2

Bialystok, Oświęcim, Poznan, Rzeszów, Śląskie, Warsaw, Wroclaw

2025-12-03

Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

7,140

Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Radom, Ruda Śląska

2025-12-01

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Lublin, Siedlce, Bialystok, Szczecin, Kielce, Lodz

2025-11-28

Recruiting

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

NCT07236099Prurigo Nodularis (PN)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

135

Bialystok, Gdansk, Kielce, Lodz, Malbork, Nowa Sól, Poznan, Rzeszów

2025-11-27

Recruiting

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

NCT07195149Chronic Coronary Syndrome, Stable Coronary Artery Disease CAD

DrugsPrasugrel·Aspirin

Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.

Phase 3

1,703

Bialystok, Bydgoszcz, Gdansk, Grudziądz, Katowice, Krakow, Lodz, Nowa Sól

2025-11-25

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

NCT07226765Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

Bialystok, Poznan, Warsaw

2025-11-25

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Bialystok, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Lublin, Oświęcim

2025-11-25

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Bialystok, Gdansk, Katowice, Krakow, Lodz, Poznan, Rzeszów, Szczecin

2025-11-14

Active, closed

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

NCT07220642Obesity, Overweight

DrugCagrilintide

Novo Nordisk A/S

Phase 3

300

Bialystok, Katowice, Lublin, Warsaw

2025-11-05

Active, closed

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644Hidradenitis Suppurativa (HS)

DrugBFB759

Bluefin Biomedicine, Inc.

Phase 2/3

210

Bialystok, Lublin, Wroclaw

2025-11-03

Active, closed

A Study With CIT-013 in HS Patients

NCT06993233Hidradenitis Suppurativa (HS)

Citryll BV

Phase 2

108

Bialystok, Gdansk, Katowice, Lodz, Poznan, Rzeszów, Wroclaw

2025-10-31

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Bialystok, Ksawerów, Piaseczno, Rzeszów, Sosnowiec

2025-10-30

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Bialystok, Gdansk, Katowice, Lublin, Poznan, Warsaw

2025-10-23

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Bialystok, Gdansk, Krakow, Poznan, Siedlce

2025-10-22

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Bialystok, Rzeszów

2025-10-20

Active, closed

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

NCT07260669Endometriosis

Gesynta Pharma AB

Phase 2

213

Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Siedlce, Skorzewo, Szczecin

2025-10-15

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Bialystok, Gdansk, Katowice, Lodz, Mysłowice, Poznan, Rzeszów, Warsaw

2025-10-15

Recruiting

COronoary Microcirculation Analysis NETwork

NCT07498231Coronary Artery Disease, Microcirculation Resistance, Microcirculation; Biomarkers; Myocardial Ischemia, Microcirculatory Dysfunction

Medical University of Bialystok

Not applicable

180

Bialystok

2025-10-10

Active, closed

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors

DrugXeomin

Merz Aesthetics GmbH

Phase 3

300

Krakow, Oświęcim, Lublin, Warsaw, Bialystok, Gdynia, Lodz, Ostrowiec Świętokrzyski

2025-10-01

Recruiting

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

NCT07022483Endometrial Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

710

Bialystok, Gdynia, Poznan, Siedlce

2025-09-30

Recruiting

Suprasorb®X+PHMB Pro vs Suprasorb®X+PHMB in Treatment of Infected Venous Leg Ulcers

NCT07211243Venous Leg Ulcer

Lohmann & Rauscher

Not applicable

150

Bialystok, Krakow, Lodz, Lublin, Ostróda, Wroclaw, Zabrze

2025-09-23

Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423Chronic Obstructive Pulmonary Disease

DrugDupilumab

Sanofi

Phase 4

218

Poznan, Bialystok, Ostrowiec Świętokrzyski

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Poznan, Torun, Wroclaw, Lublin, Puławy, Warsaw, Rzeszów, Bialystok

2025-09-22

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Poznan, Krakow, Lodz, Bialystok, Chęciny, Ostrowiec Świętokrzyski

2025-09-17

Recruiting

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Wroclaw, Piaseczno, Bialystok, Katowice, Elblag, Sosnowiec

2025-09-16

Recruiting

Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective Multicenter Non-inferiority Study Comparing Overall and Progression-free Survival.

NCT07120529Cervical Cancer, Hysterectomy

Medical University of Silesia

Observational

300

Bialystok, Katowice, Kielce, Opole, Wroclaw

2025-09-15

Recruiting

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201Palmoplantar Pustulosis

DrugDelgocitinib

LEO Pharma

Phase 2

135

Bialystok, Iwonicz-Zdrój, Lodz, Lublin, Rzeszów, Warsaw, Wroclaw

2025-09-11

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

Bialystok, Bydgoszcz, Chojnice, Chorzów, Chrzanów, Częstochowa, Dębica, Gdansk

2025-09-06

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Bialystok, Bydgoszcz, Koszalin, Warsaw

2025-09-02

By invitation

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

DrugGlyphAllo

Seaport Therapeutics

Phase 2

360

Bialystok, Bydgoszcz, Gdansk, Leszno, Poznan, Tuszyn

2025-09-02

Recruiting

Changes in Energy Expenditure in Response to Physical Activity in Healthy Adults

NCT07529132Physical Activities

Medical University of Bialystok

Observational

Bialystok

2025-09-01

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Bialystok, Gdansk, Bydgoszcz, Katowice, Lublin, Tarnów, Warsaw, Wroclaw

2025-08-19

Recruiting

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT07196501Major Depressive Disorder

DrugOsavampator

Neurocrine Biosciences

Phase 3

550

Bialystok, Bydgoszcz, Gdansk

2025-08-18

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07094516Alzheimer's Disease

DrugVHB937

Novartis Pharmaceuticals

Phase 2

Bialystok, Oświęcim, Wroclaw

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Lublin, Lodz, Warsaw, Bialystok

2025-08-06

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

Poznan, Krakow, Wroclaw, Plońsk, Sochaczew, Warsaw, Bialystok, Gdynia

2025-08-01

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Krakow, Wroclaw, Lublin, Warsaw, Bialystok, Katowice, Ossy, Rzeszów

2025-07-31

Recruiting

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515Acute Decompensated Heart Failure

DrugFurosemide

Reprieve Cardiovascular, Inc

Not applicable

400

Bialystok, Lodz, Wroclaw

2025-07-28

Recruiting

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519Ulcerative Colitis

DrugRisankizumab

AbbVie

Phase 3

120

Warsaw, Bialystok

2025-07-28

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Bialystok, Bielsko-Biala, Bydgoszcz, Chojnice, Chrzanów, Dębica, Gdynia, Katowice

2025-07-25

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Bełchatów, Bialystok, Bydgoszcz, Chojnice, Częstochowa, Elblag, Gdynia, Katowice

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Bydgoszcz, Warsaw, Bialystok, Słupsk, Olsztyn, Koszalin, Lodz

2025-07-21

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Poznan, Warsaw, Bialystok, Gdansk, Rybnik, Tuszyn

2025-07-18

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Bialystok, Warsaw

2025-07-17

Active, closed

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488Atopic Dermatitis (AD)

DrugBFB759

Bluefin Biomedicine, Inc.

Phase 2

225

Bialystok, Bydgoszcz, Chorzów, Gdansk, Grodzisk Mazowiecki, Krakow, Malbork, Ostrowiec Świętokrzyski

2025-07-15

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Poznan, Torun, Bialystok, Gdansk

2025-07-14

Recruiting

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

NCT06832722Shock, Cardiogenic

4TEEN4 Pharmaceuticals GmbH

Phase 1/2

Bialystok, Katowice, Poznan, Wroclaw

2025-07-13

Recruiting

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

NCT06904235Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy

DrugNEPA

Helsinn Healthcare SA

Phase 2

Bialystok, Bydgoszcz, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw

2025-07-07

Recruiting

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)

NCT07067437Breast Neoplasms

National Institute of Oncology, Hungary

Not applicable

250

Bialystok, Brzozów, Gliwice, Poznan, Wroclaw

2025-07-01

Recruiting

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

NCT06979375Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Wroclaw, Lublin, Bialystok, Biała Podlaska, Bielsko-Biala, Krakow, Przemyśl, Warsaw

2025-06-30

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

2,400

Bydgoszcz, Krakow, Wałbrzych, Warsaw, Bialystok, Słupsk, Olsztyn, Koszalin

2025-06-30

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Bialystok, Bydgoszcz, Chęciny, Elblag, Karczew, Katowice, Komorniki, Ksawerów

2025-06-27

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Wroclaw, Lublin, Bialystok, Szczecin, Bielsko-Biala, Krakow, Lodz, Przemyśl

2025-06-27

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Bialystok, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lodz, Lublin

2025-06-27

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Bialystok, Bydgoszcz, Chrzanów, Elblag, Gdansk, Gdynia, Giżycko, Katowice

2025-06-25

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Poznan, Katowice, Bialystok, Bydgoszcz, Krakow, Rzeszów, Wroclaw

2025-06-20

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

210

Bialystok, Szczecin, Bydgoszcz, Chorzów, Kielce, Lublin, Olsztyn, Opole

2025-06-19

Recruiting

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

NCT07065240Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

DrugGlyphAllo

Seaport Therapeutics

Phase 2

360

Bełchatów, Bialystok, Bydgoszcz, Gdansk, Katowice, Leszno, Poznan, Torun

2025-06-19

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

NCT06951698Bipolar-I Disorder With Mania or Mania With Mixed Features

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

274

Poznan, Warsaw, Bialystok, Gdansk, Rybnik, Sosnowiec, Tuszyn

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Bialystok, Poznan, Siedlce

2025-06-10

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Bialystok, Chorzów, Piaseczno, Rzeszów, Warsaw, Wołomin

2025-06-09

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Bialystok, Bydgoszcz, Gdansk, Gdynia, Jelenia Góra, Katowice, Kędzierzyn-Koźle, Krakow

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Bialystok, Bydgoszcz, Gdansk, Kielce, Lodz, Wroclaw

2025-06-04

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

Krakow, Lublin, Warsaw, Bialystok, Siemianowice Śląskie, Tychy, Lodz, Nowy Targ

2025-06-01

Active, closed

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

NCT07035093Obesity, Overweight, Chronic Low Back Pain (CLBP)

DrugRetatrutide

Eli Lilly and Company

Phase 3

586

Bialystok

2025-05-29

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Siedlce, Bialystok

2025-05-28

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

Bialystok, Gdansk, Gdynia, Katowice, Kędzierzyn-Koźle, Krakow, Lodz, Lublin

2025-05-28

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

Poznan, Siedlce, Warsaw, Bialystok, Gdansk, Gliwice, Kielce

2025-05-22

Recruiting

Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions

NCT07330622Coronary Occlusion, Percutaneous Coronary Intervention

National Institute of Cardiology, Warsaw, Poland

Observational

1,000

Bialystok, Grodzisk Mazowiecki, Inowrocław, Katowice, Krakow, Lubin, Lublin, Nowy Sącz

2025-05-21

Active, closed

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479Severe Asthma

DrugVerekitug

Upstream Bio Inc.

Phase 2

396

Wroclaw, Krakow, Tarnów, Rzeszów, Bialystok, Gdansk, Ostrowiec Świętokrzyski

2025-05-21

Active, closed

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610Hidradenitis Suppurativa (HS)

Zura Bio Inc

Phase 2

247

Bialystok, Katowice, Malbork, Poznan, Szczecin, Warsaw

2025-05-16

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

Bialystok, Gdynia, Lodz, Torun, Warszawa Targówek, Wroclaw

2025-05-14

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530Hypertension

DrugOrforglipron

Eli Lilly and Company

Phase 3

487

Bialystok, Bydgoszcz, Piotrkow Trybunalski, Przemyśl, Tarnów, Warsaw, Wroclaw

2025-04-30

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCT06948435Hypertension, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

487

Bialystok, Bydgoszcz, Piotrkow Trybunalski, Przemyśl, Tarnów, Warsaw, Wroclaw

2025-04-30

Active, closed

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422Hypertension

DrugOrforglipron

Eli Lilly and Company

Phase 3

974

Bialystok, Bydgoszcz, Piotrkow Trybunalski, Przemyśl, Tarnów, Warsaw, Wroclaw

2025-04-30

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

Krakow, Lublin, Bialystok

2025-04-16

Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401Major Depressive Disorder

DrugOsavampator

Neurocrine Biosciences

Phase 3

850

Bełchatów, Bialystok, Bydgoszcz, Gdansk, Grudziądz, Katowice

2025-04-16

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Bialystok, Elblag, Katowice, Krakow, Lodz, Olsztyn, Poznan, Skierniewice

2025-04-15

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

NCT06865105Psoriatic Arthritis

DrugsLutikizumab·Risankizumab

AbbVie

Phase 2

120

Bydgoszcz, Pruszków, Warsaw, Bialystok, Elblag

2025-04-11

Recruiting

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

NCT06943469Atopic Dermatitis (AD)

Société des Produits Nestlé (SPN)

Not applicable

400

Bialystok, Warsaw

2025-04-10

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

?ód?, Bialystok, Konin, Koszalin, Krakow, Lublin, Późna, Rzeszów

2025-04-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Poznan, Warsaw, Bialystok, Szczecin, Kielce

2025-04-09

Active, closed

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166COPD, Smoking, Tobacco Use

Philip Morris Products S.A.

Not applicable

290

Bialystok, Kajetany, Krakow, Lodz, Sochaczew, Warsaw, Wroclaw

2025-04-02

Recruiting

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT06897475Type 2 Diabetes

Eli Lilly and Company

Phase 2

200

Bialystok, Gdansk, Krakow, Lodz, Lublin, Tarnów, Warsaw, Wroclaw

2025-03-28

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Bialystok, Gdansk, Lodz, Poznan, Siedlce, Szczecin

2025-03-27

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Bialystok, Bydgoszcz, Chrzanów, Karczew, Katowice, Kielce, Krakow, Lodz

2025-03-18

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Bialystok, Gdynia

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Bialystok, Biała Podlaska, Bydgoszcz, Chojnice, Chrzanów, Częstochowa, Gdansk, Gdynia

2025-03-14

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Bialystok, Dębica, Gdynia, Katowice, Lodz, Lublin, Poznan, Warsaw

2025-03-12

Recruiting

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

NCT06688331Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1

DrugRituximab

PolTREG S.A.

Phase 2

150

Bialystok, Gdansk, Katowice, Lodz, Lublin, Opole, Rzeszów, Szczecin

2025-03-12

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Lublin, Bialystok, Gdansk, Kielce

2025-03-06

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

Bialystok, Gliwice, Józefów, Warsaw

2025-03-04

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Bialystok, Gdynia, Gmina Świecie, Jasło, Katowice, Krakow, Lodz, Lublin

2025-03-03

Recruiting

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT06830044Major Depressive Disorder (MDD)

Vanda Pharmaceuticals

Phase 3

500

Bialystok, Bydgoszcz, Gdansk, Katowice, Suchy Las, Torun

2025-03-03

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Poznan, Krakow, Katowice, Sochaczew, Warsaw, Opole, Bialystok, Bytom

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Bialystok, Gdansk, Koszalin, Lodz, Olsztyn, Przemyśl, Tomaszów Mazowiecki, Warsaw

2025-03-01

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Bialystok, Chorzów, Cracov, Gdansk, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow

2025-02-28

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn

2025-02-21

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Krakow, Wroclaw, Lublin, Warsaw, Bialystok

2025-02-12

Active, closed

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236Platinum-resistant Ovarian Cancer

DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine

Genmab

Phase 3

584

Krakow, Bialystok, Gdansk, Lodz, Poznan, Siedlce, Szczecin

2025-02-07

Active, closed

Real-life Treatment Outcomes of Ravulizumab in PNH

NCT06633536Paroxysmal Nocturnal Haemoglobinuria

DrugRavulizumab

AstraZeneca

Observational

Bialystok, Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Opole

2025-02-06

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

Bialystok, Gdansk, Gdynia, Lodz, Lublin, Piaseczno, Warsaw

2025-02-03

Recruiting

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

NCT06698796Dermatomyositis, Polymyositis

Pfizer

Phase 3

211

Warsaw, Bialystok

2025-01-22

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow

2025-01-15

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

NCT06754462Rheumatoid Arthritis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

120

Bialystok, Elblag, Lublin, Nadarzyn, Poznan, Sochaczew, Warsaw, Wroclaw

2025-01-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lodz, Lublin, Nadarzyn

2025-01-09

Active, closed

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis

Alumis Inc

Phase 3

1,680

Podlaski, Bydgoszcz, Wroclaw, Krakow, Sochaczew, Warsaw, Bialystok, Gdansk

2025-01-08

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

Bialystok, Bydgoszcz, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Krakow

2025-01-07

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib

Pfizer

Phase 3

1,035

Krakow, Bialystok, Gdynia, Koszalin, Lodz

2025-01-06

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

Warsaw, Bialystok, Krakow, Lodz, Miechów, Opole, Poznan, Ruda Śląska

2024-12-19

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Bialystok, Biała Podlaska, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole

2024-12-12

Active, closed

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619Asthma

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

649

Bialystok, Gdansk, Lodz, Maków Podhalański, Poznan, Tarnów, Wroclaw

2024-12-12

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Bialystok, Gdansk, Lodz

2024-12-09

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Bialystok, Bydgoszcz, Chorzów, Częstochowa, Gdansk, Katowice, Krakow, Lodz

2024-12-05

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Bialystok, Bydgoszcz, Lodz, Zawadzkie

2024-12-03

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

Włocławek, Lublin, Rzeszów, Bialystok, Gmina Świecie, Katowice, Lodz, Olsztyn

2024-12-02

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw

2024-11-27

Active, closed

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

NCT06444113Multiple Sclerosis

Novartis Pharmaceuticals

Phase 4

Bialystok, Kielce

2024-11-25

Recruiting

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT06701903Generalized Anxiety Disorder

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

570

Bialystok, Bydgoszcz, Gdansk, Leszno, Torun

2024-11-21

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw

2024-11-18

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Poznan, Bialystok, Chęciny, Katowice, Ostrowiec Świętokrzyski

2024-11-07

Active, closed

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173Type 2 Diabetes Mellitus (T2DM)

DrugMaridebart cafraglutide

Amgen

Phase 2

409

Bialystok, Krakow, Lublin, Staszów, Warsaw, Wroclaw

2024-11-07

Active, closed

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

NCT06662383Obesity

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

800

Poznan, Lublin, Bialystok, Ruda Śląska, Lodz

2024-11-01

Recruiting

Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy.

NCT06633250Cow Milk Protein Allergy

Société des Produits Nestlé (SPN)

Not applicable

104

Bialystok, Bydgoszcz, Janki, Krakow, Lodz, Lublin, Rzeszów, Tarnów

2024-10-25

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Bialystok, Biała Podlaska, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole

2024-10-18

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

Bialystok, Bydgoszcz, Bytom, Częstochowa, Dąbrówka, Dębica, Elblag, Gdynia

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdynia, Katowice, Krakow, Lodz

2024-10-15

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

349

Bialystok, Gdansk, Katowice, Krakow, Lublin, Pruszków, Szczecin, Warsaw

2024-10-10

Active, closed

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446Refractory or Unexplained Chronic Cough

Nocion Therapeutics

Phase 2

455

Bialystok, Bydgoszcz, Częstochowa, Ostrowiec Świętokrzyski, Strzelce Opolskie, Szczecin, Tarnów

2024-09-24

Active, closed

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Tectonic Therapeutic

Phase 2

191

Bialystok, Krakow, Lodz, Lublin, Warsaw, Wroclaw

2024-09-04

Recruiting

Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.

NCT06614790Ovarian Cancer

DrugNiraparix

Pomeranian Medical University Szczecin

Observational

300

Bialystok, Gdansk, Gliwice, Kielce, Krakow, Lublin, Opole, Siedlce

2024-09-02

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

Poznan, Wroclaw, Otwock, Warsaw, Bialystok, Lodz, Kielce

2024-08-28

Active, closed

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228Asthma

DrugsICS/LABA·Dupilumab

Regeneron Pharmaceuticals

Phase 4

120

Krakow, Wroclaw, Warsaw, Bialystok, Gdansk

2024-08-26

Active, closed

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT06284954Dermatomyositis, Myositis

DrugEmpasiprubart

argenx

Phase 2

Bialystok, Poznan, Wroclaw

2024-08-20

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Poznan, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice

2024-08-19

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Bialystok, Biała Podlaska, Krakow, Poznan, Warsaw

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Bialystok, Katowice, Krakow, Lublin, Warsaw, Wroclaw

2024-08-12

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRemigromig·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Gdansk, Bialystok, Bydgoszcz, Katowice, Krakow, Olsztyn, Tarnowskie Góry

2024-08-07

Recruiting

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

NCT06480383Generalized Anxiety Disorder

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

705

Bialystok, Bydgoszcz, Gorlice, Leszno, Poznan, Torun

2024-08-05

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Poznan, Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Szczecin, Świdnik

2024-07-31

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Poznan, Warsaw, Bialystok

2024-07-24

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Bialystok, Bydgoszcz, Elblag, Gdansk, Katowice, Kielce, Krakow, Lodz

2024-07-11

Active, closed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549Moderate to Severe Plaque Psoriasis

DrugsBimekizumab·Ustekinumab

UCB Biopharma SRL

Phase 3

176

Bialystok, Lodz, Nowa Sól, Rzeszów, Szczecin, Wroclaw

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Bydgoszcz, Krakow, Warsaw, Wieliszew, Bialystok, Gdynia, Gliwice, Szczecin

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Bialystok, Krakow, Lodz, Poznan, Warsaw, Wroclaw

2024-06-20

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Bialystok, Bydgoszcz, Chojnice, Częstochowa, Elblag, Gdansk, Gdynia, Katowice

2024-06-17

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

Bydgoszcz, Warsaw, Bialystok, Gliwice

2024-06-11

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Bialystok, Gdansk, Krakow, Lodz, Nowy Sącz, Olsztyn, Poznan, Szczecin

2024-06-03

Active, closed

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

NCT05975021Cardiogenic Shock

Windtree Therapeutics

Phase 1/2

Bialystok, Opole, Wroclaw

2024-06-01

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Bydgoszcz, Warsaw, Bialystok, Gdynia, Poland, Kielce

2024-05-03

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Bialystok, Bielsko-Biala, Bydgoszcz, Chorzów, Chrzanów, Elblag, Gdansk, Krakow

2024-04-30

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Bialystok, Katowice, Kielce, Krakow, Poznan, Warsaw, Wieliczka, Wroclaw

2024-04-29

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Bialystok, Bydgoszcz, Lublin, Przemyśl, Tarnów, Torun, Wieliszew, Wroclaw

2024-04-18

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Bydgoszcz, Siedlce, Warsaw, Wieliszew, Rzeszów, Bialystok, Gdynia, Gliwice

2024-04-14

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Bialystok, Bydgoszcz, Krakow, Lublin, Przemyśl, Tarnów, Torun, Wieliszew

2024-04-09

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Poznan, Krakow, Lublin, Warsaw, Przemyśl, Bialystok, Gdansk, Prabuty

2024-04-03

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Bialystok, Krakow, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw

2024-03-29

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsDefactinib·Avutometinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Bialystok, Gdansk, Siedlce

2024-03-18

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

731

Bialystok, Katowice, Kielce, Krakow, Olsztyn, Warsaw, Wroclaw

2024-03-09

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Bialystok, Bydgoszcz, Chrzanów, Dąbrowa Górnicza, Elblag, Gdansk, Grudziądz, Katowice

2024-03-05

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Bialystok, Gdansk, Poznan, Siedlce

2024-02-27

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Bialystok, Bydgoszcz, Chęciny, Chojnice, Częstochowa, Inowrocław, Karczew, Katowice

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Bialystok, Bystra, Gdansk, Lublin, Poznan, Prabuty, Przemyśl, Warsaw

2024-02-20

Recruiting

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

NCT06466785Anemia of Chronic Kidney Disease

DrugDarbepoetin Alfa

Genexine, Inc.

Phase 3

429

Bialystok, Brodnica, Lodz, Pszczyna, Wadowice, Warsaw, Żyrardów

2024-01-25

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

774

Bialystok, Elblag, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw

2024-01-17

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Poznan, Bydgoszcz, Krakow, Rzeszów, Bialystok, Katowice, Zabrze

2023-12-27

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Osielsko, Krakow, Warsaw, Bialystok, Katowice, Szczecin

2023-12-19

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Bialystok, Bielsko-Biala, Bydgoszcz, Gliwice, Olsztyn, Piotrkow Trybunalski, Siedlce, Tomaszów Mazowiecki

2023-12-14

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Lodz, Warsaw, Bialystok, Katowice, Szczecin

2023-12-11

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Poznan, Bydgoszcz, Krakow, Warsaw, Przemyśl, Bialystok, Gdansk, Olsztyn

2023-12-06

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Poznan, Siedlce, Warsaw, Bialystok

2023-12-06

Recruiting

Remote ECG Monitoring Post TAVI

NCT07521800TAVI(Transcatheter Aortic Valve Implantation), Remote Monitoring, Arrythmia, Atrial Fibrillation (AF)

Medical University of Silesia

Not applicable

250

Bialystok, Katowice

2023-12-01

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Bialystok, Bydgoszcz, Gdansk, Gdynia, Konin, Krakow, Legnica, Lodz

2023-11-23

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsAvutometinib·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Bialystok, Bystra, Gdynia, Gliwice, Krakow, Lodz, Lublin, Poznan

2023-11-16

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Bialystok, Bydgoszcz, Gdynia, Krakow, Lodz, Warsaw

2023-11-14

Active, closed

Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE

NCT07107074Alzheimer Disease, Early Onset

ADvantage Therapeutics

Phase 2

122

Bialystok, Bydgoszcz

2023-11-08

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Bydgoszcz, Krakow, Warsaw, Bialystok, Katowice, Szczecin, Lodz

2023-11-08

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

Lódz, Bialystok

2023-11-07

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Bydgoszcz, Krakow, Bialystok, Gdansk, Olsztyn, Będzin, Katowice, Lodz

2023-10-25

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

311

Bialystok, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw

2023-10-12

Active, closed

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

684

Bialystok, Elblag, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Osielsko, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice, Elblag

2023-10-11

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Bialystok, Biała Podlaska, Bydgoszcz, Gdansk, Gdynia, Koszalin, Krakow, Lodz

2023-10-05

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Poznan, Bialystok, Krakow, Olsztyn, Warsaw, Wroclaw

2023-10-02

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Bialystok, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw, Wroclaw

2023-09-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Bydgoszcz, Bialystok, Gdansk, Olsztyn, Lodz

2023-09-14

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

Bialystok, Piaseczno, Świdnik, Warsaw, Wroclaw

2023-09-08

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Bialystok, Gdansk, Katowice, Krakow, Warsaw, Wroclaw

2023-09-05

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269Rheumatoid Arthritis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

420

Poznan, Torun, Nowa Sól, Warsaw, Opole, Bytom, Bialystok, Bydgoszcz

2023-08-31

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

DrugAlbuterol sulfate

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,772

Bialystok, Bydgoszcz, Elblag, Gdansk, Krakow, Lodz, Lublin, Maków Podhalański

2023-08-30

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Poznan, Bydgoszcz, Siedlce, Warsaw, Bialystok, Gdansk, Gliwice, Szczecin

2023-07-19

Recruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831Endometrial Cancer

DrugNavtemadlin

Kartos Therapeutics, Inc.

Phase 2/3

268

Bialystok, Gdansk, Gliwice, Krakow, Olsztyn, Poznan, Warsaw, Wroclaw

2023-07-17

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443Moderate to Severe Asthma

DrugsICS/LABA·Povorcitinib

Incyte Corporation

Phase 2

247

Bialystok, Gdansk, Krakow, Lubin, Ostrowiec Świętokrzyski, Warsaw

2023-07-11

Active, closed

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

DrugEnvudeucitinib

Alumis Inc

Phase 2

408

Bytom, Bialystok, Bydgoszcz, Częstochowa, Krakow, Nadarzyn, Poznan, Sosnowiec

2023-06-26

Active, closed

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05776472Paroxysmal Nocturnal Hemoglobinuria

DrugPegcetacoplan

Swedish Orphan Biovitrum

Observational

165

Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Warsaw

2023-06-26

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

NCT05742607Non Small Cell Lung Cancer

DrugDurvalumab

Innate Pharma

Phase 2

Bialystok, Krąków, Lublin, Poznan, Prabuty, Warsaw

2023-06-23

Recruiting

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370Coronary Artery Disease, Heart Failure Systolic

Sunnybrook Health Sciences Centre

Not applicable

754

Bialystok, Katowice

2023-06-22

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Poznan, Krakow, Warsaw, Bialystok

2023-05-20

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Bialystok, Elblag, Katowice, Lubin, Lublin, Nowa Sól, Olsztyn, Opole

2023-04-05

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Bialystok, Krakow, Lodz, Skarżysko-Kamienna, Tarnów

2023-04-05

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Bialystok, Grudziądz, Koszalin, Lodz, Lublin, Opole, Poznan, Racibórz

2023-03-31

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

Bialystok, Bydgoszcz, Lublin, Piotrkow Trybunalski, Poznan, Słupsk, Warsaw, Wroclaw

2023-03-23

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Krakow, Bialystok, Bydgoszcz, Bygdoszcz, Chorzów, Elblag, Gdynia, Grudziądz

2023-03-09

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Bialystok, Bolesławiec, Bydgoszcz, Chelmie, Działdowo, Grodzisk Mazowiecki, Gryfice, Katowice

2023-02-15

Recruiting

Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

NCT04433052Coronary Heart Disease

Tampere University

Not applicable

12,000

Bialystok, Katowice, Krakow, Lublin, Toruniak, Warsaw

2023-02-01

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Będzin, Bialystok, Gdansk, Giżycko, Katowice, Krakow, Lodz, Lublin

2023-01-30

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258Autosomal Recessive Polycystic Kidney (ARPKD)

DrugTolvaptan

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

Warsaw, Bialystok

2023-01-23

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Bialystok, Bydgoszcz, Kalisz, Kielce, Knurów, Krakow, Lodz, Lublin

2023-01-16

Active, closed

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT05617677Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

516

Poznan, Bydgoszcz, Krakow, Nadarzyn, Warsaw, Katowice, Bialystok, Lublin

2023-01-12

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Bialystok, Lodz, Lublin, Poznan, Warsaw

2023-01-11

Recruiting

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

NCT05582876Prostate Cancer

Medical University of Bialystok

Not applicable

366

Bialystok, Bydgoszcz, Lodz, Lublin

2023-01-10

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Bialystok, Czeladź, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz

2022-12-27

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Bialystok, Katowice, Ścinawa, Warsaw, Wroclaw

2022-12-23

Active, closed

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

470

Bialystok, Częstochowa, Katowice, Krakow, Lublin, Wroclaw

2022-12-13

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Bialystok, Lodz, Poznan, Warsaw

2022-12-09

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Bialystok, Gdansk, Krakow, Lodz, Warsaw, Wroclaw

2022-11-08

Recruiting

Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer

NCT05468554Thyroid Cancer

DrugMetformin

Medical University of Bialystok

Phase 3

160

Bialystok, Kielce

2022-11-01

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Bydgoszcz, Krakow, Legnica, Lublin, Warsaw, Bialystok, Gdansk, Katowice

2022-11-01

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Bialystok, Katowice, Krakow, Lodz, Skorzewo, Warsaw

2022-10-14

Recruiting

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525Neurogenic Detrusor Overactivity

DrugVibegron

Urovant Sciences GmbH

Phase 2/3

Bialystok, Gdansk, Warsaw

2022-10-12

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

Bialystok, Bydgoszcz, Chorzów, Elblag, Gdansk, Krakow, Lodz, Lublin

2022-10-11

Active, closed

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases

DrugDonanemab

Eli Lilly and Company

Phase 3

1,500

Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Szczecin, Warsaw

2022-10-10

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Bialystok, Krakow, Lodz, Rzeszów, Szczecin, Torun, Warsaw, Wroclaw

2022-09-27

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

381

Bialystok, Kościan, Krakow, Poznan, Szczecin, Warsaw

2022-09-16

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Bialystok, Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Rzeszów, Szczecin

2022-09-13

Recruiting

Genetics of the Acute Response to Oral Semaglutide

NCT05340868PreDiabetes, Prediabetic State, Obesity

DrugsSemaglutide Pill·Semaglutide

Medical University of Bialystok

Not applicable

1,000

Bialystok

2022-09-01

Recruiting

Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

NCT05467033Kidney Biopsy

DrugsDesmopressin·NaCl

Medical University of Bialystok

Phase 3

424

Bialystok

2022-09-01

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Lublin, Sopot, Warsaw

2022-08-24

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Bialystok, Lublin, Poznan

2022-07-08

Active, closed

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

529

Bialystok, Krakow, Lublin, Nadarzyn, Olsztyn, Poznan, Torun, Warsaw

2022-06-30

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Bialystok, Krakow, Nowy Sącz, Poznan, Warsaw, Wałbrzych

2022-06-23

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Bialystok, Bydgoszcz, Bytom, Krakow, Malbork, Poznan, Warsaw

2022-06-10

Active, closed

Empagliflozin in Hypertrophic Cardiomyopathy

NCT05182658Hypertrophic Cardiomyopathy, Heart Failure

DrugDapagliflozin

National Institute of Cardiology, Warsaw, Poland

Phase 3

250

Bialystok, Warsaw

2022-06-01

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Bialystok, Bydgoszcz, Lodz, Poznan, Warsaw, Wroclaw

2022-05-16

Recruiting

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

NCT05179876Hypertension, Pulmonary

DrugsMacitentan·Selexipag

Actelion

Phase 3

280

Bialystok, Bydgoszcz, Katowice, Lodz, Lublin, Szczecin, Wroclaw

2022-05-04

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Bialystok, Bydgoszcz, Elblag, Lodz, Olsztyn, Szczecin, Warsaw

2022-04-19

Active, closed

Evaluation of the Influence of PRF (Platelet-rich Fibrin) on the Clinical Parameters and the Concentration of Selected Inflammation Mediators in GCF (Gingival Crevice Fluid) of Patients With Periodontitis

NCT06920849Periodontal Disease, Periodontitis

DrugIPRF

Medical University of Bialystok

Not applicable

Bialystok

2022-04-01

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Poznan, Warszawa, Bydgoszcz, Wroclaw, Warsaw, Bialystok, Bytom

2022-03-29

Active, closed

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636Change in Bone Mineral Density, Bone Loss

DrugDrospirenone

Insud Pharma

Phase 4

1,536

Bialystok, Katowice, Krakow, Lodz, Warsaw

2022-03-28

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Warsaw, Bialystok, Gdansk, Lodz

2022-03-28

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Bialystok, Krakow, Lodz

2022-03-15

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Lodz, Gdynia, Szczecin, Bialystok, Lublin

2022-03-04

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Bialystok, Gliwice, Katowice, Lodz, Warsaw, Wroclaw

2022-02-18

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2

310

Krakow, Bialystok, Gdynia

2022-02-17

Active, closed

Atorvastatin Effect on Reduction of COPD Exacerbations

NCT04789057Copd, COPD Exacerbation, Smoking, Gene Expression

DrugAtorvastatin

Medical University of Bialystok

Phase 4

460

Bialystok

2022-02-11

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

Poznan, Lublin, Siedlce, Warsaw, Bialystok, Gliwice, Kielce

2022-02-03

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Bialystok, Bydgoszcz, Chojnice, Chrzanów, Knurów, Krakow, Lodz, Lublin

2022-01-19

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Plewiska, Bialystok, Glogow Wielkopolski, Katowice, Lublin, Wroclaw, Zabrze

2021-12-13

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

643

Poznan, Warsaw, Bialystok, Gdansk, Gliwice, Kielce

2021-12-13

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Nowy Targ, Ostrołęka, Sosnowiec, Bialystok, Bydgoszcz, Gdansk, Gdynia, Kielce

2021-11-23

Active, closed

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

DrugsHerzuma·Perjeta·Herceptin·Adriamycin

AstraZeneca

Phase 3

927

Bialystok, Biała Podlaska, Bydgoszcz, Koszalin, Lublin, Rzeszów, Warsaw

2021-10-25

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Bialystok, Gdansk, Gdynia, Konin, Koszalin, Lodz, Tomaszów Mazowiecki, Warsaw

2021-10-18

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nadarzyn

2021-08-30

Recruiting

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

NCT04875611Nasopharyngeal Cancer

DrugsOpdivo·Nivolumab

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2

Bialystok, Gdansk, Gliwice, Kielce

2021-08-26

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Bialystok, Bielsk Podlaski, Bielsko-Biala, Bydgoszcz, Gdansk, Katowice, Krakow, Krosno

2021-08-14

Recruiting

European Disease Registry on Retinopathy of Prematurity (ROP)

NCT04939571Retinopathy of Prematurity

University Medicine Greifswald

Observational

3,000

Bialystok, Bydgoszcz, Katowice, Olsztyn, Poznan, Warsaw

2021-08-06

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Bialystok, Olsztyn

2021-08-04

By invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

760

Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw

2021-07-27

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Przemyśl, Bialystok, Gliwice

2021-06-18

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lublin, Nadarzyn, Nowa Sól

2021-06-17

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Bialystok, Bydgoszcz, Bytom, Krakow, Lublin, Malbork, Nowa Sól, Poznan

2021-05-25

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Bialystok, Gda?sk, Gliwice, Krakow, Poznan, Warsaw

2021-05-04

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Poznan, Siedlce, Warsaw, Bialystok, Gliwice, Olsztyn, Kielce

2021-01-10

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647Autoimmunity, Inflammation

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

1,000

Krakow, Wroclaw, Warsaw, Bialystok, Bydgoszcz, Poznan, Sochaczew, Torun

2020-12-22

Active, closed

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652Non-small Cell Lung Cancer

DrugsDato-DXd·Docetaxel

Daiichi Sankyo

Phase 3

605

Bialystok, Gdynia, Lublin, Olsztyn, Poznan, Prabuty, Słupsk, Warsaw

2020-12-21

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Fulvestrant

Hoffmann-La Roche

Phase 2

303

Bialystok, Gliwice, Warsaw

2020-11-27

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw

2020-11-17

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Bialystok, Bydgoszcz, Poznan

2020-10-02

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Bialystok, Grzepnica, Lublin, Olsztyn, Poznan

2020-08-04

Active, closed

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

NCT04314531Active Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

296

Bialystok, Lublin, Poznan, Warsaw

2020-07-01

Active, closed

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945Pulmonary Arterial Hypertension

DrugMacitentan

Actelion

Phase 3

935

Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Szczecin, Warsaw, Wroclaw

2020-06-30

Recruiting

Polish Registry of Diabetes (PolReD)

NCT04657367Diabetes, Obesity, PreDiabetes, Dysglycemia

Medical University of Bialystok

Observational

10,000

Bialystok

2020-02-03

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Bialystok, Brzozów, Bydgoszcz, Chorzów, Gdansk, Gdask, Krakow, Lodz

2020-01-16

Active, closed

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

NCT03997786Moderate-to-severe Chronic Plaque Psoriasis

DrugsTildrakizumab·Etanercept

Sun Pharmaceutical Industries Limited

Phase 2/3

135

Bialystok, Katowice, Lodz, Lublin, Ostrowiec Świętokrzyski, Sosnowiec, Szczecin, Warsaw

2020-01-15

Active, closed

Sperm Selection Strategies and Male-Factor Phenotypes in ICSI

NCT07825584Assisted Reproductive Technology, Assisted Reproductive Technology Outcomes

Center for Reproductive Medicine Bocian

Observational

12,561

Poznan, Lublin, Warsaw, Rzeszów, Bialystok, Gdansk, Katowice, Szczecin

2020-01-02

Recruiting

Trifecta-Kidney cfDNA-MMDx Study

NCT04239703Kidney Transplant Rejection

University of Alberta

Observational

300

Bialystok, Bydgoszcz, Gdansk, Katowice, Poznan, Szczecin, Warsaw, Wroclaw

2019-12-01

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Rzeszów, Sopot, Szczecin

2019-09-26

By invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension

United Therapeutics

Phase 3

1,000

Bialystok, Krakow, Otwock, Poznan, Wroclaw

2019-09-23

Active, closed

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339Diabetic Cardiomyopathies

Applied Therapeutics, Inc.

Phase 3

675

Wroclaw, Bialystok, Krakow, Lodz, Poznan, Radom, Rzeszów

2019-09-20

Active, closed

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 3

896

Poznan, Wroclaw, Będzin, Bialystok, Gdansk, Gdynia, Jelenia Góra, Lodz

2019-09-05

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Bialystok, Bydgoszcz, Chorzów, Gdansk, Kielce, Krakow, Lodz, Lublin

2019-08-23

Active, closed

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050Warm Autoimmune Hemolytic Anemia

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

118

Bialystok, Gdansk, Katowice, Lodz, Opole, Warsaw

2019-08-15

Active, closed

The Influence of Local Antibiotic Therapy on the Outcomes Following Periodontal Regeneration Procedures.

NCT07027137Periodontitis, Periodontal Diseases

Medical University of Bialystok

Not applicable

Bialystok

2019-08-01

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Poznan, Bydgoszcz, Tarnów, Wroclaw, Otwock, Warsaw, Bialystok, Słupsk

2019-07-24

Active, closed

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

NCT03981796Neoplasms

DrugsNiraparib·Dostarlimab·Paclitaxel·Carboplatin

Tesaro, Inc.

Phase 3

785

Bialystok, Gdynia, Lodz, Olsztyn, Poznan, Szczecin, Warsaw

2019-07-18

Active, closed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561Diabetes Mellitus, Type 2

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,500

Bialystok, Bydgoszcz, Chorzów, Gdansk, Katowice, Krakow, Lodz, Poznan

2019-05-08

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

NCT03813407Hyperkalaemia

DrugPumitamig

AstraZeneca

Phase 3

140

Bialystok, Krakow, Lodz, Warsaw

2019-04-02

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Bydgoszcz, Torun, Krakow, Grodzisk Mazowiecki, Warsaw, Bialystok, Elblag, Olsztyn

2019-03-25

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Bialystok, Gdansk, Konin, Lodz, Olsztyn, Opole, Poznan, Tomaszów Mazowiecki

2019-03-21

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

Bydgoszcz, Wroclaw, Ostrołęka, Warsaw, Wieliszew, Bialystok, Gdansk, Gdynia

2018-12-27

Active, closed

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

NCT03819465Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsDanvatirsen·Oleclumab·Volrustomig·Rilvegostomig

AstraZeneca

Phase 1

175

Bialystok, Bydgoszcz, Gdansk, Grudziądz, Lodz, Olsztyn, Tomaszów Mazowiecki, Warsaw

2018-12-27

Active, closed

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486Non-small Cell Lung Cancer NSCLC

DrugsOlaparib·Durvalumab·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 2

401

Bialystok, Lodz, Poznan, Prabuty

2018-12-21

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Warsaw, Bialystok, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin

2018-12-07

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Bialystok, Olsztyn, Warsaw

2018-12-06

Active, closed

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

NCT03706690Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

407

Bialystok, Gdansk, Poznan, Tomaszów Mazowiecki, Warsaw

2018-11-27

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

DrugsDurvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,063

Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Ostrołęka, Poznan

2018-11-16

By invitation

Białystok PLUS - Polish Longitudinal University Study

NCT03197363Cardiovascular Diseases, Diabetes, Neuro-Degenerative Disease, Obesity

Medical University of Bialystok

Observational

8,320

Bialystok

2018-11-05

Active, closed

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,246

Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Poznan, Radom

2018-09-27

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Konin, Poznan, Bydgoszcz, Krakow, Warsaw, Opole, Bialystok, Gdansk

2018-08-21

Recruiting

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850Chronic Kidney Disease; Iron Deficiency Anemia

DrugsIron sucrose·Ferumoxytol

AMAG Pharmaceuticals, Inc.

Phase 3

129

Bialystok, Krakow, Lodz

2018-08-13

Active, closed

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858Progressive Multiple Sclerosis (PMS)

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

927

Bialystok, Krakow, Lodz, Późna, Rzeszów, Warsaw, Zabrze

2018-05-28

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Bialystok, Gdansk, Grudziądz, Koszalin, Piotrkow Trybunalski, Poznan, Warsaw, Wroclaw

2018-05-14

Active, closed

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed

DrugsRucaparib·Opdivo·Nivolumab

pharmaand GmbH

Phase 3

1,097

Warsaw, Bialystok, Gdynia, Lublin, Poznan, Szczecin

2018-05-14

Active, closed

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugPacritinib

Swedish Orphan Biovitrum

Phase 3

407

Bialystok, Gdansk, Katowice, Krakow, Lodz, Lublin, Nowy Sącz, Rzeszów

2017-06-26

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

Bialystok, Lublin, Olsztyn, Warsaw

2017-03-27

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Woj. Podkarpackie

2017-02-02

Active, closed

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NCT03003962Non Small Cell Lung Carcinoma NSCLC

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

669

Bialystok, Grudziądz, Koszalin, Lublin, Mrozy, Warsaw, Wroclaw

2017-01-02

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

NCT02908906Neoplasms

DrugCetrelimab

Janssen Research & Development, LLC

Phase 1/2

234

Bialystok, Warsaw

2016-11-21

Active, closed

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV

DrugTepotinib

EMD Serono Research & Development Institute, Inc.

Phase 2

337

Bialystok, Bystra, Lublin, Olsztyn, Poznan, Warsaw

2016-09-13

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Torun, Cracow, Krakow, Wroclaw, Lublin, Grodzisk Mazowiecki, Warsaw, Bialystok

2015-12-01

Active, closed

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318Prostate Cancer

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,052

Bialystok, Bydgoszcz, Krakow, Kutno, Lodz, Lublin, Siedlce, Sochaczew

2015-11-27

Active, closed

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516Prostatic Neoplasms

DrugsGnRH·Bicalutamide·Apalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,503

Bialystok, Bydgoszcz, Gdynia, Gliwice, Kielce, Lodz, Olsztyn, Poznan

2015-11-19

Active, closed

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454Atopic Dermatitis

DrugDupilumab

Regeneron Pharmaceuticals

Phase 3

880

Ostrowiec Świętokrzyski, Wroclaw, Krakow, Katowice, Bialystok, Bydgoszcz, Chorzów, Gdansk

2015-10-15

Recruiting

The Bialystok Bariatric Surgery Study

NCT04634591Obesity, Diabetes Mellitus, Metabolic Syndrome, Dyslipidemias

Medical University of Bialystok

Observational

1,000

Bialystok

2015-09-10

Active, closed

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703Breast Neoplasms

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

669

Gdansk, Bialystok, Lodz

2014-07-22

Active, closed

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204Prostatic Neoplasms

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,207

Bialystok, Bydgoszcz, Gdansk, Kutno, Lodz, Poznan, Szczecin, Torun

2013-10-14

Active, closed

Short- and Long-term Health Effects of Air Pollution in Poland

NCT05198492Acute Coronary Syndrome, Atrial Fibrillation, Kidney Diseases, Particulate Matter Inhalation Injury

Medical University of Bialystok

Observational

8,300,000

Bialystok

2011-01-01

Recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110IGF1 Deficiency

Esteve Pharmaceuticals, S.A.

Observational

500

Bialystok, Gdansk, Lublin, Poznan, Rzeszów, Szczecin

2008-12-09

Active, closed

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437Breast Cancer

DrugFulvestrant

AstraZeneca

Phase 3

736

Bialystok, Lodz, Poznan

2005-02-13

By invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

NCT02699736HIV, Hepatitis B, Hepatitis C, AIDS

Copenhagen University Hospital, Rigshospitalet

Observational

23,000

Bialystok, Chorzów, Gdansk, Lodz, Poznan, Szczecin, Warsaw, Wroclaw

1994-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/bialystok

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 384 of those studies with a site in Bialystok.

How many clinical trials are recruiting in Bialystok?

191 of the 384 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 5 have not yet opened recruitment, 178 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bialystok), 384 studies
Phase	Studies	Recruiting	Share
Phase 3	257	117	66.9%
Phase 2	59	31	15.4%
Observational	21	14	5.5%
Not applicable	20	16	5.2%
Phase 2/3	10	5	2.6%
Phase 4	8	3	2.1%
Phase 1/2	5	3	1.3%
Phase 1	4	2	1%

Most active sponsors

Lead sponsors with the most studies (Bialystok)
Lead sponsor	Studies	Recruiting
AstraZeneca	52	28
Janssen Research & Development, LLC	23	7
Merck Sharp & Dohme LLC	23	10
Eli Lilly and Company	20	10
Medical University of Bialystok	19	13
Novo Nordisk A/S	16	11
Novartis Pharmaceuticals	11	4
AbbVie	9	5
Bristol-Myers Squibb	9	5
Pfizer	9	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.